VNRX Quote, Financials, Valuation and Earnings

InfuSystems Holdings has a net margin of -1226.82% compared to VolitionRX's net margin of 2.76%. VolitionRX's return on equity of -- beat InfuSystems Holdings's return on equity of 4.33%.

VolitionRX has a consensus price target of $3.37, signalling upside risk potential of 501.2%. On the other hand InfuSystems Holdings has an analysts' consensus of $14.13 which suggests that it could grow by 154.51%. Given that VolitionRX has higher upside potential than InfuSystems Holdings, analysts believe VolitionRX is more attractive than InfuSystems Holdings.

VolitionRX has a beta of 1.092, which suggesting that the stock is 9.182% more volatile than S&P 500. In comparison InfuSystems Holdings has a beta of 1.755, suggesting its more volatile than the S&P 500 by 75.5%.

VolitionRX has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystems Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. VolitionRX pays -- of its earnings as a dividend. InfuSystems Holdings pays out -- of its earnings as a dividend.

VolitionRX quarterly revenues are $474.5K, which are smaller than InfuSystems Holdings quarterly revenues of $33.8M. VolitionRX's net income of -$5.8M is lower than InfuSystems Holdings's net income of $933K. Notably, VolitionRX's price-to-earnings ratio is -- while InfuSystems Holdings's PE ratio is 55.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VolitionRX is 36.22x versus 0.89x for InfuSystems Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of -1226.82% compared to VolitionRX's net margin of -18.58%. VolitionRX's return on equity of -- beat Retractable Technologies's return on equity of -16.83%.

VolitionRX has a consensus price target of $3.37, signalling upside risk potential of 501.2%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that VolitionRX has higher upside potential than Retractable Technologies, analysts believe VolitionRX is more attractive than Retractable Technologies.

VolitionRX has a beta of 1.092, which suggesting that the stock is 9.182% more volatile than S&P 500. In comparison Retractable Technologies has a beta of 2.083, suggesting its more volatile than the S&P 500 by 108.265%.

VolitionRX has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. VolitionRX pays -- of its earnings as a dividend. Retractable Technologies pays out -3.32% of its earnings as a dividend.

VolitionRX quarterly revenues are $474.5K, which are smaller than Retractable Technologies quarterly revenues of $10.3M. VolitionRX's net income of -$5.8M is lower than Retractable Technologies's net income of -$1.9M. Notably, VolitionRX's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VolitionRX is 36.22x versus 0.59x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -1226.82% compared to VolitionRX's net margin of -4291.67%. VolitionRX's return on equity of -- beat Catheter Precision's return on equity of -65.84%.

VolitionRX has a consensus price target of $3.37, signalling upside risk potential of 501.2%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 419.62%. Given that VolitionRX has higher upside potential than Catheter Precision, analysts believe VolitionRX is more attractive than Catheter Precision.

VolitionRX has a beta of 1.092, which suggesting that the stock is 9.182% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.541, suggesting its less volatile than the S&P 500 by 154.132%.

VolitionRX has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. VolitionRX pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

VolitionRX quarterly revenues are $474.5K, which are larger than Catheter Precision quarterly revenues of $96K. VolitionRX's net income of -$5.8M is lower than Catheter Precision's net income of -$4.1M. Notably, VolitionRX's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VolitionRX is 36.22x versus 1.03x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -1226.82% compared to VolitionRX's net margin of -10.04%. VolitionRX's return on equity of -- beat Xtant Medical Holdings's return on equity of -35.34%.

VolitionRX has a consensus price target of $3.37, signalling upside risk potential of 501.2%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 264.58%. Given that VolitionRX has higher upside potential than Xtant Medical Holdings, analysts believe VolitionRX is more attractive than Xtant Medical Holdings.

VolitionRX has a beta of 1.092, which suggesting that the stock is 9.182% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.747%.

VolitionRX has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. VolitionRX pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

VolitionRX quarterly revenues are $474.5K, which are smaller than Xtant Medical Holdings quarterly revenues of $31.5M. VolitionRX's net income of -$5.8M is lower than Xtant Medical Holdings's net income of -$3.2M. Notably, VolitionRX's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VolitionRX is 36.22x versus 0.55x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.